Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380448237> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4380448237 abstract "Abstract Background and Aims Inhibitors of the renin-angiotensin system (RAS), sodium-glucose transporter (SGLT)-2, and the mineralocorticoid receptor (MR) have all demonstrated renoprotective effects in large clinical trials of diabetes-related CKD. Furthermore, dual RAS/SGLT2 blockade showed additive renoprotective effects also in non-diabetic CKD. We hypothesized that triple RAS/SGLT2/MR blockade would be even superior to dual RAS/SGLT2 blockade in non-diabetic CKD. Method We performed a “no touch” preclinical randomized controlled trial in Col4a3-deficient mice with spontaneous and progressive CKD (registry ID: PCTE0000266). Treatments were administered as food admix from 6-14 weeks of age at the following estimated doses: 10 mg/kg ramipril, 30 mg/kg empagliflozin, 10 mg/kg finerenone. The prespecified primary endpoint was total lifespan up to uremic death. Ancillary studies addressed baseline histology, and mechanistic studies on a subset of mice after 2.5 weeks of treatment. Results At the time of randomization, Col4a3-/- mice had albuminuria, elevated serum creatinine, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Total lifespan was 63.7 ± 9.99 days (vehicle), 77.25 ± 5.34 days (ramipril), 80.3 ± 10.98 days (ramipril+empagliflozin), and 103.05 ± 20.28 days (triple therapy), respectively. Artificial intelligence-based histopathology and RNA sequencing analysis documented a potent anti-sclerotic, -inflammation and -fibrotic effect of the triple combination. Conclusion Adding finereone to dual RAS/SGLT2 blockade significantly prolongs uremia-free lifespan even when started at an advanced stage of Alport nephropathy. Triple RAS/SGLT2/MR blockade could be a potent treatment strategy to prolong uremia-free lifespan in patients with CKD related to Alport syndrome and possibly other progressive kidney disorders." @default.
- W4380448237 created "2023-06-14" @default.
- W4380448237 creator A5005720030 @default.
- W4380448237 creator A5010478903 @default.
- W4380448237 creator A5022640003 @default.
- W4380448237 creator A5024783922 @default.
- W4380448237 creator A5029559509 @default.
- W4380448237 creator A5039968865 @default.
- W4380448237 creator A5046254027 @default.
- W4380448237 creator A5049305761 @default.
- W4380448237 creator A5054261599 @default.
- W4380448237 creator A5072521927 @default.
- W4380448237 creator A5082196815 @default.
- W4380448237 creator A5083905896 @default.
- W4380448237 date "2023-06-01" @default.
- W4380448237 modified "2023-09-27" @default.
- W4380448237 title "#4534 FINERENONE ADDED TO RAS/SGLT2 BLOCKADE FOR NON-DIABETIC CHRONIC KIDNEY DISEASE: RESULTS OF A PRECLINICAL DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL" @default.
- W4380448237 doi "https://doi.org/10.1093/ndt/gfad063a_4534" @default.
- W4380448237 hasPublicationYear "2023" @default.
- W4380448237 type Work @default.
- W4380448237 citedByCount "0" @default.
- W4380448237 crossrefType "journal-article" @default.
- W4380448237 hasAuthorship W4380448237A5005720030 @default.
- W4380448237 hasAuthorship W4380448237A5010478903 @default.
- W4380448237 hasAuthorship W4380448237A5022640003 @default.
- W4380448237 hasAuthorship W4380448237A5024783922 @default.
- W4380448237 hasAuthorship W4380448237A5029559509 @default.
- W4380448237 hasAuthorship W4380448237A5039968865 @default.
- W4380448237 hasAuthorship W4380448237A5046254027 @default.
- W4380448237 hasAuthorship W4380448237A5049305761 @default.
- W4380448237 hasAuthorship W4380448237A5054261599 @default.
- W4380448237 hasAuthorship W4380448237A5072521927 @default.
- W4380448237 hasAuthorship W4380448237A5082196815 @default.
- W4380448237 hasAuthorship W4380448237A5083905896 @default.
- W4380448237 hasBestOaLocation W43804482371 @default.
- W4380448237 hasConcept C126322002 @default.
- W4380448237 hasConcept C126894567 @default.
- W4380448237 hasConcept C134018914 @default.
- W4380448237 hasConcept C159641895 @default.
- W4380448237 hasConcept C170493617 @default.
- W4380448237 hasConcept C2775887513 @default.
- W4380448237 hasConcept C2776174234 @default.
- W4380448237 hasConcept C2777180221 @default.
- W4380448237 hasConcept C2778468042 @default.
- W4380448237 hasConcept C2778653478 @default.
- W4380448237 hasConcept C2779888176 @default.
- W4380448237 hasConcept C2779922275 @default.
- W4380448237 hasConcept C2780091579 @default.
- W4380448237 hasConcept C2781184683 @default.
- W4380448237 hasConcept C555293320 @default.
- W4380448237 hasConcept C71924100 @default.
- W4380448237 hasConcept C84393581 @default.
- W4380448237 hasConceptScore W4380448237C126322002 @default.
- W4380448237 hasConceptScore W4380448237C126894567 @default.
- W4380448237 hasConceptScore W4380448237C134018914 @default.
- W4380448237 hasConceptScore W4380448237C159641895 @default.
- W4380448237 hasConceptScore W4380448237C170493617 @default.
- W4380448237 hasConceptScore W4380448237C2775887513 @default.
- W4380448237 hasConceptScore W4380448237C2776174234 @default.
- W4380448237 hasConceptScore W4380448237C2777180221 @default.
- W4380448237 hasConceptScore W4380448237C2778468042 @default.
- W4380448237 hasConceptScore W4380448237C2778653478 @default.
- W4380448237 hasConceptScore W4380448237C2779888176 @default.
- W4380448237 hasConceptScore W4380448237C2779922275 @default.
- W4380448237 hasConceptScore W4380448237C2780091579 @default.
- W4380448237 hasConceptScore W4380448237C2781184683 @default.
- W4380448237 hasConceptScore W4380448237C555293320 @default.
- W4380448237 hasConceptScore W4380448237C71924100 @default.
- W4380448237 hasConceptScore W4380448237C84393581 @default.
- W4380448237 hasIssue "Supplement_1" @default.
- W4380448237 hasLocation W43804482371 @default.
- W4380448237 hasOpenAccess W4380448237 @default.
- W4380448237 hasPrimaryLocation W43804482371 @default.
- W4380448237 hasRelatedWork W1569125154 @default.
- W4380448237 hasRelatedWork W2009602329 @default.
- W4380448237 hasRelatedWork W2021055445 @default.
- W4380448237 hasRelatedWork W2061298156 @default.
- W4380448237 hasRelatedWork W2376102491 @default.
- W4380448237 hasRelatedWork W3130716591 @default.
- W4380448237 hasRelatedWork W4230335818 @default.
- W4380448237 hasRelatedWork W4233572510 @default.
- W4380448237 hasRelatedWork W4236388730 @default.
- W4380448237 hasRelatedWork W4380625599 @default.
- W4380448237 hasVolume "38" @default.
- W4380448237 isParatext "false" @default.
- W4380448237 isRetracted "false" @default.
- W4380448237 workType "article" @default.